<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/33E895DD-DE8B-40DB-9353-1A4FA804A605/chart/price-vs-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/33E895DD-DE8B-40DB-9353-1A4FA804A605/chart/price-vs-fair-value"/></p>
<p>納斯達克 GM:FLGT 1 年股價與公允價值</p>
<p>探索 Fulgent Genetics 的社區公允價值並選擇您的觀點</p>
<p>當美國醫療行業近一半的公司市銷率（或稱&#34;P/S&#34;）低於 1 倍時，您可能會考慮 <strong>Fulgent Genetics, Inc.</strong>（NASDAQ:FLGT）作為一個潛在的避開對象，因為其市銷率為 2.1 倍。然而，市銷率可能高是有原因的，需要進一步調查以確定其是否合理。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
<p>查看我們對 Fulgent Genetics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/315621345-ps-multiple-vs-industry-1-dark-2/1754475961719?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/315621345-ps-multiple-vs-industry-1-dark-2/1754475961719"/></p>
<p>納斯達克 GM:FLGT 市銷率與行業比較 2025 年 8 月 6 日</p>
<h3>Fulgent Genetics 的表現如何</h3>
<p>最近一段時間，Fulgent Genetics 的表現並不理想，因為其收入增長速度低於大多數其他公司。也許市場預計未來的收入表現將會逆轉，這提升了市銷率。然而，如果情況並非如此，投資者可能會發現自己為該股票支付了過高的價格。</p>
<p>如果您想了解分析師對未來的預測，您應該查看我們關於 Fulgent Genetics 的 <strong>免費</strong> 報告。</p>
<h2>Fulgent Genetics 的收入增長預測是否足夠？</h2>
<p>為了證明其市銷率的合理性，Fulgent Genetics 需要實現超過行業的顯著增長。</p>
<p>回顧過去一年的收入增長，公司實現了 4.3% 的可觀增長。然而，遺憾的是，收入與三年前相比總共下降了 67%，這令人失望。因此，不幸的是，我們必須承認公司在這段時間內未能很好地實現收入增長。</p>
<p>展望未來，覆蓋該公司的三位分析師的估計顯示，收入在明年應增長 11%。而行業僅預測增長 7.7%，公司有望實現更強的收入結果。</p>
<p>考慮到這一點，理解為什麼 Fulgent Genetics 的市銷率相對於同行較高並不困難。顯然，股東們不願意拋售可能面臨更繁榮未來的股票。</p>
<h2>最終結論</h2>
<p>僅僅使用市銷率來判斷您是否應該出售股票並不明智，但它可以作為公司未來前景的實用指南。</p>
<p>我們對 Fulgent Genetics 的分析顯示，其市銷率仍然高於同行，基於其強勁的未來收入。目前，股東們對市銷率感到滿意，因為他們相當有信心未來的收入不會受到威脅。除非這些條件發生變化，否則他們將繼續為股價提供強有力的支持。</p>
<p>那麼其他風險呢？每家公司都有風險，我們發現了 <strong>Fulgent Genetics 的 2 個警告信號</strong>（其中 1 個是重要的！）您應該瞭解。</p>
<p><strong>如果您對過去盈利增長穩健的公司感興趣</strong>，您可能希望查看這份 <strong>免費</strong> 的其他盈利增長強勁且市盈率低的公司集合。</p>

FLGT

<p>Fulgent Genetics, Inc.（納斯達克代碼：FLGT）的市銷率（P/S）為 2.1 倍，高於許多醫療行業的公司，其中近一半的公司市銷率低於 1 倍。儘管最近的收入增長為 4.3%，但該公司在三年內的收入卻下降了 67%。分析師預測明年的收入增長將達到 11%，超過行業平均水平的 7.7%。高市銷率反映了市場對未來收入增長的信心，儘管仍存在潛在風險，包括為該公司識別出的兩個警示信號</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/33E895DD-DE8B-40DB-9353-1A4FA804A605/chart/price-vs-fair-value" alt="" original-src="https://images.simplywall.st/company/33E895DD-DE8B-40DB-9353-1A4FA804A605/chart/price-vs-fair-value"/></p>
<p>NasdaqGM:FLGT 1 Year Share Price vs Fair Value</p>
<div class="lb-trans"><p>納斯達克 GM:FLGT 1 年股價與公允價值</p>
</div><p>Explore Fulgent Genetics's Fair Values from the Community and select yours</p>
<div class="lb-trans"><p>探索 Fulgent Genetics 的社區公允價值並選擇您的觀點</p>
</div><p>When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or &#34;P/S&#34;) below 1x, you may consider <strong>Fulgent Genetics, Inc.</strong>(NASDAQ:FLGT) as a stock to potentially avoid with its 2.1x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>當美國醫療行業近一半的公司市銷率（或稱&#34;P/S&#34;）低於 1 倍時，您可能會考慮 <strong>Fulgent Genetics, Inc.</strong>（NASDAQ:FLGT）作為一個潛在的避開對象，因為其市銷率為 2.1 倍。然而，市銷率可能高是有原因的，需要進一步調查以確定其是否合理。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
</div><p>View our latest analysis for Fulgent Genetics</p>
<div class="lb-trans"><p>查看我們對 Fulgent Genetics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/315621345-ps-multiple-vs-industry-1-dark-2/1754475961719" alt="" original-src="https://images.simplywall.st/asset/chart/315621345-ps-multiple-vs-industry-1-dark-2/1754475961719"/></p>
<p>NasdaqGM:FLGT Price to Sales Ratio vs Industry August 6th 2025</p>
<div class="lb-trans"><p>納斯達克 GM:FLGT 市銷率與行業比較 2025 年 8 月 6 日</p>
</div><h3>How Fulgent Genetics Has Been Performing</h3>
<div class="lb-trans"><h3>Fulgent Genetics 的表現如何</h3>
</div><p>Recent times haven't been great for Fulgent Genetics as its revenue has been rising slower than most other companies. Perhaps the market is expecting future revenue performance to undergo a reversal of fortunes, which has elevated the P/S ratio. However, if this isn't the case, investors might get caught out paying too much for the stock.</p>
<div class="lb-trans"><p>最近一段時間，Fulgent Genetics 的表現並不理想，因為其收入增長速度低於大多數其他公司。也許市場預計未來的收入表現將會逆轉，這提升了市銷率。然而，如果情況並非如此，投資者可能會發現自己為該股票支付了過高的價格。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Fulgent Genetics.</p>
<div class="lb-trans"><p>如果您想了解分析師對未來的預測，您應該查看我們關於 Fulgent Genetics 的 <strong>免費</strong> 報告。</p>
</div><h2>Is There Enough Revenue Growth Forecasted For Fulgent Genetics?</h2>
<div class="lb-trans"><h2>Fulgent Genetics 的收入增長預測是否足夠？</h2>
</div><p>In order to justify its P/S ratio, Fulgent Genetics would need to produce impressive growth in excess of the industry.</p>
<div class="lb-trans"><p>為了證明其市銷率的合理性，Fulgent Genetics 需要實現超過行業的顯著增長。</p>
</div><p>If we review the last year of revenue growth, the company posted a worthy increase of 4.3%. Still, lamentably revenue has fallen 67% in aggregate from three years ago, which is disappointing. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenue over that time.</p>
<div class="lb-trans"><p>回顧過去一年的收入增長，公司實現了 4.3% 的可觀增長。然而，遺憾的是，收入與三年前相比總共下降了 67%，這令人失望。因此，不幸的是，我們必須承認公司在這段時間內未能很好地實現收入增長。</p>
</div><p>Shifting to the future, estimates from the three analysts covering the company suggest revenue should grow by 11% over the next year. With the industry only predicted to deliver 7.7%, the company is positioned for a stronger revenue result.</p>
<div class="lb-trans"><p>展望未來，覆蓋該公司的三位分析師的估計顯示，收入在明年應增長 11%。而行業僅預測增長 7.7%，公司有望實現更強的收入結果。</p>
</div><p>With this in mind, it's not hard to understand why Fulgent Genetics' P/S is high relative to its industry peers. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.</p>
<div class="lb-trans"><p>考慮到這一點，理解為什麼 Fulgent Genetics 的市銷率相對於同行較高並不困難。顯然，股東們不願意拋售可能面臨更繁榮未來的股票。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最終結論</h2>
</div><p>Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.</p>
<div class="lb-trans"><p>僅僅使用市銷率來判斷您是否應該出售股票並不明智，但它可以作為公司未來前景的實用指南。</p>
</div><p>Our look into Fulgent Genetics shows that its P/S ratio remains high on the merit of its strong future revenues. Right now shareholders are comfortable with the P/S as they are quite confident future revenues aren't under threat. Unless these conditions change, they will continue to provide strong support to the share price.</p>
<div class="lb-trans"><p>我們對 Fulgent Genetics 的分析顯示，其市銷率仍然高於同行，基於其強勁的未來收入。目前，股東們對市銷率感到滿意，因為他們相當有信心未來的收入不會受到威脅。除非這些條件發生變化，否則他們將繼續為股價提供強有力的支持。</p>
</div><p>And what about other risks? Every company has them, and we've spotted <strong>2 warning signs for Fulgent Genetics</strong> (of which 1 is significant!) you should know about.</p>
<div class="lb-trans"><p>那麼其他風險呢？每家公司都有風險，我們發現了 <strong>Fulgent Genetics 的 2 個警告信號</strong>（其中 1 個是重要的！）您應該瞭解。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果您對過去盈利增長穩健的公司感興趣</strong>，您可能希望查看這份 <strong>免費</strong> 的其他盈利增長強勁且市盈率低的公司集合。</p>
</div>

Fulgent Genetics, Inc.（納斯達克股票代碼：FLGT）的市銷率符合市場預期